Tamara A. Favorito Acquires 3,175 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Key Points

• Director Purchase: Zevra Therapeutics Director Tamara Favorito purchased $24,733.25 worth of stock, increasing her ownership by 441.59% to a total of 3,894 shares valued at approximately $30,334.26.
• Stock Performance: Zevra Therapeutics' stock is currently trading at $7.26, with a market capitalization of $407.54 million and 52-week range between $6.19 and $13.16.
• Analyst Ratings: The company has received mixed analyst ratings, with eight analysts rating it a "Buy" and one a "Hold," despite some downgrades in recent reports; the consensus target price stands at $23.71.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) Director Tamara A. Favorito acquired 3,175 shares of Zevra Therapeutics stock in a transaction that occurred on Friday, September 12th. The shares were purchased at an average cost of $7.79 per share, with a total value of $24,733.25. Following the completion of the acquisition, the director owned 3,894 shares of the company's stock, valued at $30,334.26. The trade was a 441.59% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Zevra Therapeutics Price Performance

ZVRA stock traded down $0.27 during midday trading on Friday, hitting $7.67. 2,692,514 shares of the stock were exchanged, compared to its average volume of 1,275,063. The stock's 50-day moving average price is $10.01 and its 200-day moving average price is $8.91. The stock has a market cap of $430.52 million, a price-to-earnings ratio of -36.52 and a beta of 1.56. Zevra Therapeutics, Inc. has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Woodline Partners LP grew its position in shares of Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock valued at $34,571,000 after purchasing an additional 476,032 shares during the period. Adage Capital Partners GP L.L.C. grew its position in Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company's stock valued at $36,720,000 after acquiring an additional 550,000 shares during the period. Rubric Capital Management LP grew its position in Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company's stock valued at $17,253,000 after acquiring an additional 740,584 shares during the period. AIGH Capital Management LLC grew its position in Zevra Therapeutics by 82.4% during the first quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company's stock valued at $10,771,000 after acquiring an additional 649,495 shares during the period. Finally, Geode Capital Management LLC grew its position in Zevra Therapeutics by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company's stock valued at $10,948,000 after acquiring an additional 9,275 shares during the period. Hedge funds and other institutional investors own 35.03% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ZVRA. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. HC Wainwright began coverage on Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price target for the company. Zacks Research cut Zevra Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, August 18th. JMP Securities cut their price target on Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating for the company in a report on Wednesday, August 13th. Finally, Wall Street Zen cut Zevra Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, September 13th. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Zevra Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $23.71.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.